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integration of both quantity and quality of life into a single
analysis to be used for treatment comparisons. METHODS:
EORTC QLQ C-30, FACT-G&P were used to collect
QoL data for 288 subjects with asymptomatic hormone
refractory prostate cancer as part of a randomized, dou-
ble-blind, placebo-controlled dose ranging study of atra-
sentan, a selective endothelin-A receptor antagonist. Both
instruments were administered at baseline and then at ev-
ery six weeks until disease progression. The missing QoL
domain scores were imputed by last observation carried
forward method. The QoL domain scores were converted
to a unit scale, range 0–1, with a higher score indicating
improved QoL. The conversion was implemented with a
linear affine transformation of original score according
to Ware et. al. Each subject’s QADFS was computed as
the sum of the product QoL weights and the duration for
which the patient experienced that level of QoL. These
QADFS times were then analyzed with Kaplan-Meier
methodology. In order to analyze the effect of adminis-
trative censoring on the results an area under the curve
analysis for each QoL domain was implemented with the
assumption of equal length of follow-up (365 days). RE-
SULTS: The mean QADFS were estimated and compared
amongst the three treatment groups. These comparisons
yielded results that were robust to the choice of QoL do-
mains and the length of follow-up. CONCLUSIONS: Multi-
dimensional QoL instruments may be used to provide a
summary index for assessing the response of novel inter-
ventions for cancer patients. It accounts for patient’s QoL
for the duration of the trial unlike the traditional (e.g.,
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OBJECTIVE: Effective antisecretory drugs are available
to treat GERD, and result in dramatic improvement of
pyrosis over placebo. Assessing a similar improvement of
HRQL would appear of value. METHOD: A critical ap-
praisal of published controlled trials was performed us-
ing a checklist. RESULTS: Although trials comparing
proton pump inhibitors (PPI) to placebo or to H2-block-
ers or cisapride showed a clinically significant difference
in the rate of complete relief of pyrosis, none was able to
show a clear and unbiased HRQL improvement. For
each trial, several or all of the following issues that may
help one to have confidence in study results are not pre-
sented or are missing: justification of the choice of ques-
tionnaires; hypotheses of changes in HRQL scores and
power estimation (even if HRQL assessment is a second-
ary endpoint); justification of the use of several question-
naires (are they covering different concepts?); statistical
analysis plan; description and imputation of missing data,
and intent to treat analysis (e.g. 408 patients among 599
randomized in a trial are analyzed for HRQL with no ex-
planation about missing data); adjustment for multiple sta-
tistical comparisons; presentation of all the scores. Generic
questionnaires (Psychological General Well Being is the
most frequently used) result most often in non significant
differences or findings without clinical significance (effect
size  0.30). This raises the uncertainty of questionnaire
responsiveness, knowing that pyrosis is largely improved
and that the sample size of trials ranges from 300 to 800.
Using the specific questionnaire, Gastrointestinal Symp-
tom Rating Scale, leads to significant results, but it may be
argued that this questionnaire is not simply a symptom
scale, because only two items on the questionnaire concern
bother about pyrosis and regurgitation. CONCLUSION:
There is concern to conclude that despite a large improve-
ment of pyrosis, especially with PPI, there is no definite
demonstration that HRQL is improved in GERD.
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OBJECTIVE: Patient-reported symptom severity mea-
sures are important for evaluating the effectiveness of
treatments for gastrointestinal diseases because they are
the only measures in clinical evaluation that directly re-
flect the patient experience. The objective of this study is
to describe the development and initial testing of a new
patient self-report instrument, the Patient Assessment of
Upper GastroIntestinal Disorders-Symptom Severity In-
dex (PAGI-SYM) in subjects with gastroesophageal re-
flux disease (GERD) or dyspepsia. METHODS: Instru-
ment content was based on an extensive review of the
published literature and interviews with patients and cli-
nicians. A sample of 448 persons with GERD (249) or
dyspepsia (199) were identified and recruited from a
large population survey. Using telephone interviews, sub-
jects completed the PAGI-SYM, the SF-36, and a measure
of patient-rated change in GI-related symptoms, the
Overall Treatment Effect Scale (OTE). Two-week repro-
ducibility was evaluated in 68 subjects. RESULTS: The
37-item PAGI-SYM is comprised of 6 subscales: heart-
burn, reflux/regurgitation, nausea/vomiting, abdominal
pain, bloating/early satiety, and other symptoms. Sub-
scale internal consistency reliability was good (alpha 
0.74 to 0.92) with the exception of the two-item sub-
